{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"groups":[{"description":"Cycle 1: Ixazomib: 4mg/day 1, 8, 15, Cyclophosphamide: 50 mg/day continuous daily, Dexamethasone: 20 mg/day 1, 8, 15 Cycles 2-6: Ixazomib: 4mg/day 1, 4, 8, 11, 15, 18, Cyclophosphamide: 50 mg/day continuous, daily, Dexamethasone: 20 mg/day 1, 4, 8, 11, 15, 18\n\nMaintenance:\n\nIxazomib at 4 mg days 1, 8 and 15 of a 28 day cycle for 1 ½ years\n\nIxazomib: Cycle 1:\n\nIxazomib: 4mg/day 1, 8, 15\n\nCycles 2-6:\n\nIxazomib: 4mg/day 1, 4, 8, 11, 15, 18,\n\nMaintenance:\n\nIxazomib at 4 mg days 1, 8 and 15 of a 28 day cycle for 1 ½ years\n\nCyclophosphamide: Cycle 1:\n\nCyclophosphamide: 50 mg/day continuous daily\n\nCycles 2-6:\n\nCyclophosphamide: 50 mg/day continuous daily\n\nDexamethasone: Cycle 1:\n\nDexamethasone: 20 mg/day 1, 8, 15\n\nCycles 2-6:\n\nDexamethasone: 20 mg/day 1, 4, 8, 11, 15, 18","id":"OG000","title":"Ixazomib Regimen"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Through study treatment completion, an average of 2 years","title":"Evaluation of the Response Rate of Ixazomib With Metronomic Cyclophosphamide and Dexamethasone for First-line Treatment of Multiple Myeloma.","type":"PRIMARY","unitOfMeasure":"Participants"}